Danbury Hospital is among more than 40 sites in the US participating in a National Institute of Health trial to identify promising therapeutic treatments against COVID-19. The trial involves biological and drug treatments compared to a placebo group. Lenzilumab is a first-in-class recombinant monoclonal antibody that's being studied as a biological treatment. Remdesivir is a drug that's been used in treatment but is being studied further. The end date for the trial is December of this year.